Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas

International Journal of Oncology

Volumn 13, Issue 4, 1998, Pages 717-724

  Galanis, E ^a   Buckner, J ^a   Kimmel, D ^a   Jenkins, R ^a   Alderete, B ^a   O'Fallon, J ^a   Wang, C H ^a   Scheithauer, B W ^a   James, C D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Astrocytomas; C MYC; CDK4; Cyclin D; EGFR; GBM; Gene amplification; Gliomas; MDM2; MET; N MYC; PDGFR

Indexed keywords

ARTICLE; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; DNA PROBE; GENE AMPLIFICATION; GLIOMA; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR GENE; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GLIOMA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOGENES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 0031671411     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.4.717     Document Type: Article

References (43)

1. Furnari FB, Huang H-JS and Cavenee WK: Genetics and malignant progression of human brain tumours. Cancer Surv 25: 233-275, 1995.
2. Bigner SH, Humphrey PA, Wong AJ, et al: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50: 8017-8022, 1990.
3. Westermark B, Heldin C-H and Nister M: Platelet-derived growth factor in human glioma. Glia 15: 257-263, 1995.
4. Fischer U, Muller HW, Sattler HP, Feiden K, Zang KD and Meese E: Amplification of the MET gene in glioma. Genes Chromosomes Cancer 12: 63-65, 1995.
5. Banerjee M, Dinda AK, Sinha S, Sarkar C and Mathur M: c-myc oncogene expression and cell proliferation in mixed oligoastrocytoma. Int J Cancer 65: 730-733, 1996.
6. Biemat W, Kleihues P, Yonekawa Y and Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997.
7. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS and Collins VP: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303, 1994.
8. He J, Reifenbcrg G, Liu L, Collins VP and James CD: Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 11: 91-96, 1994.
9. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, et al: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression, gene expression. Oncogene 8: 3447-3457, 1993.
10. Chakrabarty A, Bridges LR and Gray S: Cyclin Dl in astrocytic tumours: an immunohistochemical study. Neuropathol Appl Neurobiol 22: 311-316, 1996.
11. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS and James CD: CDK4 amplification is an alternative mechanism to pi6 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994.
12. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P and Ohgaki H: Overexpression of the EGF receptor and p53 mutations arc mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224, 1996.
13. Workman P, D'Incalci M, Bursch W, Harrap KR, Hawkings RE and Neidle S: European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (part 2). Eur J Cancer 30A: 1148-1160, 1994.
14. Langdon SP and Smyth JF: Inhibition of cell signaling pathways. Cancer Treat Rev 21: 65-89, 1995.
15. Gibbs JB and Oliff A: Pharmaceutical research in molecular oncology. Cell 79: 193-198, 1994.
16. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, et al: Recombinant iminunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phase display. Proc Natl Acad Sci USA 93: 14815-14820, 1996.
17. Reist CJ, Archer GE, Kurpad SN, et al: Tumor-specific antiepidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55: 4375-4382, 1995.
18. Kleihues P, Burger PC and Scheithauer BW: Histologic Typing of Tumours of the Central Nervous System. Springer Verlag, New York, 1993.
19. Daumas-Duport C, Scheithauer B, O'Fallon J and Kelly P: Grading of astrocytomas: a simple and reproducible method. Cancer 62: 2152-2165, 1988.
20. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, et al: Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551, 1988.
21. Bergerheim U, Nordenskjold M and Collins VP: Deletion mapping in human renal cell carcinoma. Cancer Res 49: 1390-1396, 1989.
22. Feinberg AP and Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6-13, 1989.
23. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor-alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991.
24. Khatib ZA, Matsushime MV, Valentine M, Shapiro DN, Sherr CJ and Look AT: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53: 5535-5541, 1991.
25. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, Obrien SJ, et al: Identification of an amplified, highly expressed gene in a human glioma. Science 236: 70-73, 1987.
26. Leffak IM and James CD: Opposite replication polarity of the germline c-myc gene in HeLa cells compared with that of two Burkitt lymphoma cell lines. Mol Cell Biol 9: 586-593, 1989.
27. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Amer Statist Assn 53: 457-481, 1958.
28. Peto R and Peto J: Asymptotically efficient rank invariant procedures (with discussion). J Roy Statist Soc Ser A Stat 135: 185-207, 1972.
29. Le Blanc M and Crowley J: Relative risk trees for censored survival data. Biometrics 48: 411-425, 1992.
30. James CD, Carlbom E, Nordenskjold M, Collins VP and Cavenee WK: Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 86: 2858-2862, 1989.
31. Louis DN, von Deimling A, Chung RY, Rubio M-P, Whaley JM, Eibl RH, et al: Comparative study of p53 gene and protein alterations in human astrocytomas. J Neuropathol Exp Neurol 52: 31-38, 1993.
32. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, et al: Amplification of epidermal-growth-factor-rcceptor gene correlates with different growth behavior in human glioblastoma. Int J Cancer 56: 72-77, 1994.
33. Torp SH, Helseth E, Dalen A and Unsgaard G: Relationships between Ki-67 labeling index, amplification of epidermal growth factor receptor gene, and prognosis in human glioblastoma. Acta Neurochir 177: 182-186, 1992.
34. Leenstra S, Bijlsma EK, Troost D, Oosting J, Westerveld A, Bosch DA, et al: Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Cancer 70: 684-689, 1994.
35. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, et al: Lack of prognostic relevance of alterations in the epidermal growth factor-transforming growth factor-α pathway in human astrocytic gliomas. J Neurosurg 85: 634-641, 1996.
36. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W and Collins VP: Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 149: 29-35, 1996.
37. James CD, Carlbom E, Dumanski JP, et al: Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551, 1988.
38. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1992.
39. Von Deimling A, Louis DN, von Ammon K, Petersen I, et al: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77: 295-301, 1992.
40. Li J, Yen C, Liaw DN, Podsypanina K, Bose S, Wang SI, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1876-1878, 1997.
41. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Lignon AH, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
42. Wang SI, Pue J, Li J, Bruce JN, Cairns P, Sidransky D, et al: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183-4186, 1997.
43. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrab J, An H-X, et al: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55: 822-831, 1996.